Camrelizumab
Based on 5 publication(s) in Google Scholar
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al.
For research use only. We do not sell to patients.
- Purity: 98.80%
- CAS No.: 1798286-48-2
- Molecular Weight:143.69 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Camrelizumab
More
Biological Activity
Description
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
PDCD1/PD-1/CD279
In Vitro
In a T cell proliferation assay using tuberculin treated peripheral blood mononuclear cells, Camrelizumab induces a T cell proliferation at an EC50 of 0.11 nM. In a similar assay measuring IFN-gamma secretion, Camrelizumab induces IFN-gamma production at an EC50 of 0.38 nM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG4 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
Chemical Information
-
CAS No. 1798286-48-2
-
Appearance Solid
-
Molecular Weight 143.69 kDa
-
Color White to light yellow
-
SMILES
[Camrelizumab]
-
Synonyms
SHR-1210; INCSHR1210
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
-
Oncogene
Epstein-Barr virus causes vascular abnormalities in epithelial malignancies through upregulating ANXA3-HIF-1α-VEGF pathway. [Abstract]2024 Jul;43(28):2143-2159. PMID: 38778160 -
Int Immunopharmacol
UBTF facilitates acute myeloid leukemia development and immune escape via PD-L1 regulation. [Abstract]2025 Apr 16:152:114433. PMID: 40080926 -
Molecules
2024 Oct 14;29(20):4862. PMID: 39459229 -
Front Oncol
Monocarboxylate transporter upregulation in induced regulatory T cells promotes resistance to anti-PD-1 therapy in hepatocellular carcinoma patients. [Abstract]2022 Jul 28;12:960066. PMID: 35965549
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Kuimin Mei, et al. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial. J Immunother Cancer. 2021 Mar;9(3):e002191. [Content Brief]
[2]. Jason D Lickliter, et al.A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia. Drug Des Devel Ther [Content Brief]
[3]. Caicun Zho, et al.Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 2021 Mar;9(3):305-314. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)